ストックスクリーナーアプリを入手
0.23
3.56%
-0.0085
アフターアワーズ：
.23
前日終値:
$0.2385
開ける：
$0.241
24時間の取引高:
1.13M
Relative Volume:
0.44
時価総額：
$12.69M
収益：
$30.99M
当期純損益:
$-141.41M
株価収益率:
-1.5333
EPS:
-0.15
ネットキャッシュフロー:
$-118.12M
1週間 パフォーマンス:
-12.48%
1か月 パフォーマンス:
-25.57%
6か月 パフォーマンス:
-82.96%
1年 パフォーマンス:
-97.52%
1日の値動き範囲:
$0.23
$0.2472
1週間の範囲:
$0.23
$0.2583
52週間の値動き範囲:
$0.23
$11.26
Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile
名前
Marinus Pharmaceuticals Inc
セクター
電話
484-801-4670
住所
5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA
MRNS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNS
Marinus Pharmaceuticals Inc
|
0.23 | 12.69M | 30.99M | -141.41M | -118.12M | -2.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-09-23 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-08-14 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2024-04-16 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2024-04-15 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-01-20 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-09-30 | 開始されました | Truist | Buy |
| 2020-07-01 | 開始されました | Cowen | Outperform |
| 2020-07-01 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-09 | 開始されました | Craig Hallum | Buy |
| 2019-12-20 | 開始されました | Oppenheimer | Outperform |
| 2019-03-05 | 再開されました | Jefferies | Buy |
| 2019-02-27 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-02-06 | 開始されました | Leerink Partners | Outperform |
| 2018-07-02 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-03-20 | 開始されました | Mizuho | Buy |
| 2018-02-15 | 開始されました | H.C. Wainwright | Buy |
| 2017-12-14 | 開始されました | Laidlaw | Buy |
| 2016-08-10 | 繰り返されました | Jefferies | Buy |
| 2016-06-14 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2016-03-08 | 繰り返されました | Stifel | Buy |
| 2015-12-17 | 開始されました | RBC Capital Mkts | Outperform |
| 2015-11-17 | 開始されました | Jefferies | Buy |
| 2015-10-30 | 繰り返されました | Oppenheimer | Outperform |
| 2015-08-05 | 繰り返されました | Oppenheimer | Outperform |
すべてを表示
Marinus Pharmaceuticals Inc (MRNS) 最新ニュース
Marinus Pharma stock hits 52-week low at $0.23 - Investing.com India
Marinus Pharma stock hits 52-week low at $0.23 By Investing.com - Investing.com Australia
Layoff Tracker: Editas Will Cut 60% of Staff - BioSpace
Marinus Pharmaceuticals' SWOT analysis: epilepsy drug maker's stock faces pivotal moment - Investing.com
Marinus Pharma stock hits 52-week low at $0.26 amid steep decline - Investing.com
Marinus Pharma stock hits 52-week low at $0.26 amid steep decline By Investing.com - Investing.com South Africa
Marinus Pharmaceuticals faces Nasdaq delisting risk - Investing.com
Marinus Pharmaceuticals faces Nasdaq delisting risk By Investing.com - Investing.com Nigeria
Marinus Pharmaceuticals' SWOT analysis: stock faces challenges amid pipeline setbacks By Investing.com - Investing.com South Africa
Marinus Pharmaceuticals' SWOT analysis: stock faces challenges amid pipeline setbacks - Investing.com India
MRNS (Marinus Pharmaceuticals) Enterprise Value : $31.67 Mil (As of Dec. 02, 2024) - GuruFocus.com
MRNS (Marinus Pharmaceuticals) Revenue per Share : $0.55 (TTM As of Sep. 2024) - GuruFocus.com
Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MR - GuruFocus.com
MRNS (Marinus Pharmaceuticals) Net Income : $-140.49 Mil (TTM As of Sep. 2024) - GuruFocus.com
Marinus Pharmaceuticals (LTS:0JYL) COGS-to-Revenue : 0.08 (As of Sep. 2024) - GuruFocus.com
Levi & Korsinsky Notifies Marinus Pharmaceuticals, Inc. Investor - GuruFocus.com
CDKL5 Deficiency Disorder Market Revenue to Expand Significantly by 2034, States DelveInsight Report | Marinus Pharma, Takeda, Zogenix, Inc., UCB, Ultragenyx Pharma - The Globe and Mail
CDKL5 Deficiency Disorder Market Revenue to Expand - openPR
Marinus Pharmaceuticals Reports Q3 2024 Financial Results and Strategic Developments - MSN
MRNS (Marinus Pharmaceuticals) Degree of Operating Leverage : 65.26 (As of Jun. 2024) - GuruFocus.com
Marinus Pharmaceuticals Third Quarter 2024 Earnings: Revenues Disappoint - Simply Wall St
US$1.86: That's What Analysts Think Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Is Worth After Its Latest Results - Yahoo Finance
Marinus Pharmaceuticals Lays Off 45% of Employees - BioSpace
Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit - TipRanks
Marinus Pharmaceuticals Reports Q3 Growth in ZTALMY Revenue - TipRanks
Marinus Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Marinus Pharmaceuticals' SWOT analysis: navigating challenges in rare epilepsy stock - Investing.com India
Marinus Pharmaceuticals: Q3 Earnings Snapshot - Darien Times
Marinus Pharmaceuticals (MRNS) Reports Q3 Loss, Misses Revenue Estimates - MSN
Marinus Pharmaceuticals Inc Reports Q3 2024 Revenue of $8.54M, G - GuruFocus.com
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results - The Bakersfield Californian
Marinus Pharmaceuticals Faces Setback with Phase 3 TrustTSC Trial - MSN
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment - Investing.com Canada
Greenlane Holdings to Distribute CURB’s Innovative Inhalation Device: A Game-Changer? - BP Journal
Marinus Pharmaceuticals' SWOT analysis: rare epilepsy drug maker's stock faces pivotal moment By Investing.com - Investing.com South Africa
Marinus Pharmaceuticals Inc (MRNS) 財務データ
収益
当期純利益
現金流量
EPS
Marinus Pharmaceuticals Inc (MRNS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pfanstiel Steven | CFO AND COO |
Aug 05 '24 |
Sale |
1.13 |
4,657 |
5,262 |
79,773 |
| Shafer Christina | CHIEF COMMERCIAL OFFICER |
Aug 05 '24 |
Sale |
1.14 |
3,820 |
4,355 |
67,406 |
| MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. |
Aug 05 '24 |
Sale |
1.13 |
3,621 |
4,092 |
60,263 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER |
Aug 05 '24 |
Sale |
1.13 |
4,828 |
5,456 |
72,725 |
| Braunstein Scott | CHAIRMAN AND CEO |
Aug 05 '24 |
Sale |
1.13 |
12,145 |
13,724 |
298,667 |
| Braunstein Scott | CHAIRMAN AND CEO |
Mar 27 '24 |
Option Exercise |
4.28 |
50,000 |
214,000 |
273,512 |
| Shafer Christina | CHIEF COMMERCIAL OFFICER |
Feb 20 '24 |
Sale |
9.56 |
2,153 |
20,583 |
60,308 |
| MANNING MARTHA E | SVP, GEN. COUNSEL & CORP. SEC. |
Feb 20 '24 |
Sale |
9.57 |
1,894 |
18,126 |
52,966 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER |
Feb 16 '24 |
Sale |
9.98 |
2,814 |
28,084 |
66,635 |
| Pfanstiel Steven | CFO AND COO |
Feb 16 '24 |
Sale |
9.97 |
3,092 |
30,827 |
71,697 |
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):